Announcements Trials
Browse Landscape

Phase

Phase 1 15Phase 1/2 4Phase 2 1

Status

Completed 6Terminated 4Unknown 2Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Breast Neoplasms 103Neoplasms 100Leukemia, Myeloid, Acute 88Melanoma 84Multiple Myeloma 81Neoplasm Metastasis 80Recurrence 68Ovarian Neoplasms 65Prostatic Neoplasms 59Lymphoma 59Colorectal Neoplasms 58Lymphoma, Non-Hodgkin 55Leukemia 55Pancreatic Neoplasms 50Lung Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 42Myelodysplastic Syndromes 41Carcinoma, Renal Cell 39Squamous Cell Carcinoma of Head and Neck 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Glioblastoma 35Lymphoma, Large B-Cell, Diffuse 34Triple Negative Breast Neoplasms 33Carcinoma, Hepatocellular 33Stomach Neoplasms 29Small Cell Lung Carcinoma 27Lymphoma, Follicular 27Brain Neoplasms 26Lymphoma, Mantle-Cell 25

Interventions

Nivolumab 3Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Advanced Cancer × Clear all
NCT03446040 2025-09-18

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Terminated
92 enrolled 31 charts

Advanced Cancer

NCT03110107 2025-04-24

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
376 enrolled 56 charts

Advanced Cancer

NCT05154630 2024-01-18

Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Terminated
8 enrolled
Sarcoma

Advanced Cancer

NCT02341625 2022-08-18

A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
126 enrolled 30 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡